P/E ratio for Hologic (HOLX)
P/E ratio as of June 2023 (TTM): 26.2
According to Hologic's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 26.1722. At the end of 2021 the company had a P/E ratio of 11.4.
P/E ratio history for Hologic from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 11.4 | -16.5% |
| 2020 | 13.7 | -75.66% |
| 2019 | 56.1 | -304.89% |
| 2018 | -27.4 | -347.4% |
| 2017 | 11.1 | -67.15% |
| 2016 | 33.7 | -42.49% |
| 2015 | 58.6 | -60.54% |
| 2014 | 149 | |
| 2012 | -58.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 32.7 | 24.84% | 🇺🇸 USA |
 Abbott Laboratories ABT | 28.1 | 7.27% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | 33.4 | 27.76% | 🇺🇸 USA |
 Becton Dickinson BDX | 46.7 | 78.54% | 🇺🇸 USA |
 Boston Scientific BSX | 85.9 | 228.14% | 🇺🇸 USA |
 General Electric GE | -257 | -1,082.80% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 16.5 | -36.88% | 🇺🇸 USA |
 Philips PHG | -7.92 | -130.28% | 🇳🇱 Netherlands |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.